Brief: Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea

Inventiva SA

20/09/2023 21:05

Sept 20 (Reuters) - Inventiva SA  IVAA.PA :
    * INVENTIVA AND HEPALYS PHARMA, INC. ANNOUNCE EXCLUSIVE
LICENSING
AGREEMENT TO DEVELOP AND COMMERCIALIZE LANIFIBRANOR IN JAPAN AND
SOUTH KOREA
    * INVENTIVA HAS OPTION TO ACQUIRE ALL OUTSTANDING SHARES OF
HEPALYS PHARMA, INC., AT A PRE-AGREED MULTIPLE OF POST-MONEY
VALUATION
    * UNDER AGREEMENT, INVENTIVA WILL RECEIVE A $10 MILLION
UPFRONT
PAYMENT, AND IS ELIGIBLE TO RECEIVE UP TO $ 231 MILLION
    * IN EVENT HEPALYS RECEIVES AN OFFER TO SELL LICENSE OR
RIGHTS
RELATED TO LANIFIBRANOR, INVENTIVA HAS A RIGHT OF FIRST REFUSAL
    * IN PARALLEL OF INCORPORATION OF HEPALYS PHARMA, INVENTIVA
HAS
EXERCISED ITS RIGHT TO OWN 30% OF COMPANY

Source text for Eikon:  ID:nGNE9Qg72v 
Further company coverage:  IVAA.PA 

 ((Reuters.Briefs@thomsonreuters.com;))